UBS Group
SQZ

UBS Group’s SQZ Biotechnologies Company SQZ Stock Holding History

UBS Group’s Portfolio SQZ Stock Details SQZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,410
Closed -$381 – 10361
2023
Q2 		$381 Sell
1,410
-1,214
-46% -$689 ﹤0.01% 8265
2023
Q1 		$1.47K Buy
+2,624
New +$1.93K ﹤0.01% 8732
2022
Q4 		– Sell
-3,337
Closed -$8K – 11475
2022
Q3 		$8K Buy
3,337
+344
+11% +$1.03K ﹤0.01% 8799
2022
Q2 		$10K Buy
+2,993
New +$10.8K ﹤0.01% 8062
2022
Q1 		– Sell
-14,277
Closed -$128K – 11257
2021
Q4 		$128K Buy
14,277
+7,277
+104% +$89.2K ﹤0.01% 6078
2021
Q3 		$101K Buy
7,000
+3,233
+86% +$43.8K ﹤0.01% 5829
2021
Q2 		$54K Buy
3,767
+2,314
+159% +$30.2K ﹤0.01% 6367
2021
Q1 		$20K Buy
1,453
+523
+56% +$10.6K ﹤0.01% 7407
2020
Q4 		$27K Buy
+930
New +$23.7K ﹤0.01% 6731

Other funds holding SQZ

AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group's SQZ Position: Q3 2023 in Review

UBS Group sold out of SQZ Biotechnologies Company (SQZ) in Q3 2023, closing a stake of 1,410 shares — an estimated $381 sold.

UBS Group first reported a position in SQZ in Q4 2020 and held it in 9 quarters. The position peaked at $128K in Q4 2021. 5 funds tracked by Wall St. Rank hold SQZ as of Q3 2023.

  • UBS Group reported no remaining SQZ Biotechnologies Company position as of Q3 2023 after selling out during the quarter.
  • UBS Group sold 1,410 SQZ Biotechnologies Company shares in Q3 2023, an estimated $381.
  • UBS Group first reported a position in SQZ Biotechnologies Company in Q4 2020 and held it in 9 quarters.
  • UBS Group's SQZ Biotechnologies Company position peaked at $128K in Q4 2021.
  • 5 funds tracked by Wall St. Rank held SQZ Biotechnologies Company as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.